Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Glasdegib - Pfizer

Next Previous
Drug Profile

Glasdegib - Pfizer

Alternative Names: 1095173-27-5; DAURISMO; PF 04; PF-04449913; PF-4449913

Latest Information Update: 16 Jan 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Pfizer
  • Developer Grupo Espanol de Trasplante Hematopoyetico y Terapia Celular; H. Lee Moffitt Cancer Center and Research Institute; Pfizer; Yale University
  • Class Antineoplastics; Benzimidazoles; Phenylurea compounds; Piperidines; Small molecules
  • Mechanism of Action Hedgehog cell signalling pathway inhibitors; SMO protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Acute myeloid leukaemia; Myelodysplastic syndromes
  • New Molecular Entity Yes

Highest Development Phases

  • Registered Acute myeloid leukaemia
  • Phase II Chronic myelomonocytic leukaemia; Myelodysplastic syndromes; Myelofibrosis
  • Phase I/II Glioblastoma; Graft-versus-host disease
  • No development reported Cancer; Haematological malignancies; Solid tumours

Most Recent Events

  • 13 Sep 2024 Updated efficacy and adverse events data from a phase Ib/II GEINOGLAS trial for Glioblastoma presented at the 49th European Society for Medical Oncology Congress (ESMO-2024)
  • 28 Dec 2023 Pfizer completes the phase I trial in Haematological-malignancies (Late-stage disease, Monotherapy, Second-line therapy or greater), Acute-myeloid-leukaemia (Combination therapy, First-line therapy), Myelodysplastic-syndromes (Combination therapy, First-line therapy) in Japan (NCT02038777)
  • 29 Nov 2023 Grupo Espanol in collaboration with Pfizer completes a phase Ib/II GEINOGLAS trial for Glioblastoma (Combination therapy, First-line therapy) in Spain (PO) (NCT03466450) (EudraCT2017-002410-31)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top